Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma

Lorenzo Falchi; Martin Hutchings; Carmelo Carlo-Stella; Franck Morschhauser; Michael Dickinson; Guillaume Cartron; Cyrus Khan; Monica Tani; Joaquin Martinez-Lopez; Nancy L. Bartlett; Antonio Salar; Joshua D. Brody; Sirpa Leppä; Aurelien Berthier; Martine Kallemeijn; James Relf; Fabiola Bene Tchaleu; Linda Lundberg; Emmanuel Bachy.

doi:10.3324/haematol.2024.286257

Open access journal of the Ferrata-Storti Foundation, a non-profit organization

Letters to the Editor

Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma

Lorenzo Falchi
Martin Hutchings
Carmelo Carlo-Stella
Franck Morschhauser
Michael Dickinson
Guillaume Cartron
Cyrus Khan
Monica Tani
Joaquin Martinez-Lopez
Nancy L. Bartlett
Antonio Salar
Joshua D. Brody
Sirpa Leppä
Aurelien Berthier
Martine Kallemeijn
James Relf
Fabiola Bene Tchaleu
Linda Lundberg
Emmanuel Bachy.

Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

Rigshospitalet and University of Copenhagen, Copenhagen, Denmark

Humanitas University and IRCCS Humanitas Research Hospital, Milan

Hôpital Claude Huriez and CHU de Lille, Lille

Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, VIC

CHU de Montpellier, Montpellier

Allegheny Health Network, Pittsburgh, PA

Ospedale Santa Maria delle Croci, Ravenna

Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center (CNIO), Complutense University Madrid, imas12, Madrid

Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO

Hospital del Mar, Passeig Maritim, Barcelona

Tisch Cancer Institute, New York, NY

University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki

F. Hoffmann-La Roche Ltd, Basel

Roche Products Ltd, Welwyn Garden City

Genentech, Inc., South San Francisco, CA, USA and

F. Hoffmann-La Roche Ltd, Basel

Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon

Haematologica Early view Nov 28, 2024 https://doi.org/10.3324/haematol.2024.286257

Abstract

Not available.

Figures & Tables

Article Information

Early view : Letters to the Editor

DOI

https://doi.org/10.3324/haematol.2024.286257

Pubmed

39605203

Published

2024-11-28

Published By

Ferrata Storti Foundation, Pavia, Italy

Print ISSN

0390-6078

Online ISSN

1592-8721

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views

202

PDF Downloads

Statistics from Altmetric.com

No Data

Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma

Abstract

Figures & Tables

Article Information

Article Usage

Statistics from Altmetric.com

Download Citation

Navigate

For Authors

For Reviewers

For Advertisers

Education

Privacy

More